{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.49","value":"75.4"},{"groupId":"OG001","spread":"12.63","value":"75.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"433"},{"groupId":"OG001","value":"439"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.77","value":"0.4"},{"groupId":"OG001","spread":"10.69","value":"3.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"347"},{"groupId":"OG001","value":"319"}],"units":"Participants"}],"title":"Change at Cycle 2, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.58","value":"0.8"},{"groupId":"OG001","spread":"11.34","value":"3.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"338"},{"groupId":"OG001","value":"289"}],"units":"Participants"}],"title":"Change at Cycle 3, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.79","value":"-0.6"},{"groupId":"OG001","spread":"10.34","value":"2.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"327"},{"groupId":"OG001","value":"244"}],"units":"Participants"}],"title":"Change at Cycle 4, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.00","value":"-0.5"},{"groupId":"OG001","spread":"10.82","value":"2.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"319"},{"groupId":"OG001","value":"227"}],"units":"Participants"}],"title":"Change at Cycle 5, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.37","value":"-1.9"},{"groupId":"OG001","spread":"10.75","value":"1.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"299"},{"groupId":"OG001","value":"203"}],"units":"Participants"}],"title":"Change at Cycle 6, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.69","value":"-1.9"},{"groupId":"OG001","spread":"10.13","value":"2.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"269"},{"groupId":"OG001","value":"182"}],"units":"Participants"}],"title":"Change at Cycle 7, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.29","value":"2.9"},{"groupId":"OG001","spread":"12.27","value":"3.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"250"}],"units":"Participants"}],"title":"Change at End of Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"433"},{"groupId":"OG001","value":"439"}],"units":"Participants"}],"description":"Pulse rate was measured with the participant in the seated position after the participant had been sitting quietly for at least 5 minutes.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with aRCC received avelumab 10 mg/kg, IV at Q2W in a 6-week cycle plus axitinib 5 mg, orally BID. Each treatment cycle was 42 days.","id":"OG000","title":"Avelumab + Axitinib"},{"description":"Participants with aRCC received sunitinib 50 mg orally, QD on a schedule of 4 weeks on treatment followed by 2 weeks off treatment (schedule 4/2 in 6-week cycles). Each treatment cycle was of 42 days.","id":"OG001","title":"Sunitinib"}],"paramType":"MEAN","populationDescription":"Safety analysis set included all participants who received at least one dose of study drug. Here \"Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure. \"Number Analyzed\" signifies number of participants evaluable for the specified timepoints.","reportingStatus":"POSTED","timeFrame":"Baseline (pre-dose on Day 1 of Cycle 1), Day 1 of Cycle 2, 3, 4, 5, 6, 7, EOT visit (maximum up to approximately 89 months) (each cycle=42 days)","title":"Change From Baseline in Vital Signs - Pulse Rate at Day 1 of Cycle 2, 3, 4, 5, 6, 7 and EOT Visit","type":"SECONDARY","unitOfMeasure":"beats per minute"}